PK-modifying anchors significantly alter clearance kinetics, tissue distribution, and efficacy of therapeutics siRNAs-Reference-Cited by-同舟云学术

PK-modifying anchors significantly alter clearance kinetics, tissue distribution, and efficacy of therapeutics siRNAs

Published:2022-09 Issue: Volume:29 Page:116-132
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Godinho Bruno M.D.C.,Knox Emily G.,Hildebrand Samuel,Gilbert James W.,Echeverria Dimas,Kennedy Zachary,Haraszti Reka A.,Ferguson Chantal M.,Coles Andrew H.,Biscans Annabelle,Caiazzi Jillian,Alterman Julia F.,Hassler Matthew R.,Khvorova Anastasia

Funder

ALS Association

National Institutes of Health

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference39 articles.

1. The era of RNA interference medicines: the clinical landscape of synthetic gene silencing drugs;Godinho;Saúde Tecnol.,2019

2. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis;Adams;N. Engl. J. Med.,2018

3. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria;Balwani;N. Engl. J. Med.,2020

4. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs;Morrissey;Nat. Biotechnol.,2005

5. Metabolism studies of unformulated internally [3H]-labeled short interfering RNAs in mice;Christensen;Drug Metab. Dispos.,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1;British Journal of Clinical Pharmacology;2024-08-07

2. A programmable dual-targeting siRNA scaffold supports potent two-gene modulation in the central nervous system;Nucleic Acids Research;2024-05-10

3. LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo;Pharmaceutics;2024-04-17

4. RNAi-based drug design: considerations and future directions;Nature Reviews Drug Discovery;2024-04-03

5. A programmable dual-targeting di-valent siRNA scaffold supports potent multi-gene modulation in the central nervous system;2023-12-19